MENU
Showcases Stock ranks Forex

Immunogen Inc (IMGN)
5.39  -0.06 (-1.1%) 08-08 16:00
Open: 5.51 Pre. Close: 5.45
High: 5.53 Low: 5.18
Volume: 2,033,333 Market Cap: 1,190M
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.
Prices Prediction (Update @5:00pm)
If tomorrow: Open lower Open higher
High: 5.534 - 5.562 5.562 - 5.58
Low: 5.116 - 5.152 5.152 - 5.174
Close: 5.337 - 5.393 5.393 - 5.428
Stock Technical Analysis
Overall:     
Target: Six months: 6.47
One year: 7.56
Support: Support1: 4.84
Support2: 4.40
Resistance: Resistance1: 5.54
Resistance2: 6.47
Pivot: 5.08
Moving Averages: MA(5): 5.18
MA(20): 5.13
MA(100): 4.56
MA(250): 5.38
MACD: MACD(12,26): 0.15
Signal(12,26,9): 0.15
%K %D: %K(14,3): 90.31
%D(3): 73.57
RSI: RSI(14): 58.96
52-Week: High: 7.77
Low: 3.1
Change(%): 3.7
Average Vol(K): 3-Month: 3551
10-Days: 2919
Price, MAs and Bollinger Bands
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.

[ IMGN ] has closed below upper band by 21.8%. Bollinger Bands are 20.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
Stock chart
Stock News
Sun, 07 Aug 2022
Stephens Inc. AR Has $69000 Holdings in ImmunoGen, Inc. (NASDAQ:IMGN) - Defense World

Mon, 01 Aug 2022
ImmunoGen, Inc. (IMGN) Q2 2022 Earnings Call Transcript - AlphaStreet

Sun, 31 Jul 2022
ImmunoGen, Inc. (NASDAQ:IMGN) Given Consensus Rating of “Hold” by Analysts - Defense World

Fri, 29 Jul 2022
ImmunoGen: Q2 Earnings Snapshot - The Pioneer

Fri, 29 Jul 2022
ImmunoGen, Inc. (IMGN) CEO Mark Enyedy on Q2 2022 Results - Earnings Call Transcript - Seeking Alpha

Wed, 27 Jul 2022
Kestra Advisory Services LLC Purchases 2985 Shares of ImmunoGen, Inc. (NASDAQ:IMGN) - Defense World

Financial Analysis
Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Exchange:  NASDAQ Global Select
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 220.71
Shares Float (M) 171.68
% Held by Insiders 0.40
% Held by Institutions 95.25
Shares Short (K) 14860
Shares Short Prior Month (K) 16020
Stock Financials
EPS -0.590
Book Value (p.s.) 1.130
Profit Margin -179.64
Operating Margin -170.72
Return on Assets (ttm) -26.4
Return on Equity (ttm) -101.0
Qtrly Rev. Growth -16.4
Gross Profit (p.s.) -0.368
Sales Per Share 0.405
EBITDA (p.s.) -0.683
Qtrly Earnings Growth
Operating Cash Flow (M) -186.31
Levered Free Cash Flow (M) -97.83
Stock Valuation
PE Ratio -9.14
PEG Ratio
Price to Book value 4.77
Price to Sales 13.30
Price to Cash Flow -6.39
Stock Dividends
Dividend
Dividend Yield
Dividend Growth

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android